Anthera Pharmaceuticals Inc. (ANTH)

Company Description

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. Clinical-stage program includes a Phase 2, blisibimod study. Blisibimod targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others.

COMPANY ADDRESS
25801 Industrial Blvd.
Suite B
Hayward, CA 94545
United States

COMPANY PHONE
510-856-5600

COMPANY WEBSITE



Get BioInvest's perspective on Anthera's CEO


Latest Company News

Anthera Pharma to be 'opportunistic' with capital raising Seeking Alpha - Jun 16, 2017 Speaking to Bloomberg, Anthera Pharma (ANTH -2.1%) CEO Craig Thompson says there's no apparent reason for this week's rally (up more than 20% at one point). [...]
Fri, Jun 16, 2017 7:18:00 PM, Continue reading at the source
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Just Jumped: What's Next? Insider Financial - Jun 15, 2017 In mid May, a week or so after the company had carried out a reverse split, we highlighted Anthera Pharmaceuticals Inc (NASDAQ:ANTH) as potentially being worth a punt. Anthera Pharmaceuticals Inc. (ANTH) Soars 20.37% on June 13 - Equities.com Could Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) wear out? - FinancialsTrend [...]
Thu, Jun 15, 2017 5:28:00 AM, Continue reading at the source
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Is Getting Cheaper: Is It Still ... Insider Financial - Apr 17, 2017 Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is one we've looked at a couple of times in the past, and one we've taken something of a contrarian position on as a result of this coverage. [...]
Mon, Apr 17, 2017 6:56:00 PM, Continue reading at the source
BRIEF-Sabby Management LLC reports 8.06 pct passive stake in Anthera ... Reuters - Mar 15, 2017 NEW YORK, June 8 The Federal Reserve's plan to start reducing the size of its balance sheet later this year may be limited by the resulting upward pressure on money market rates, according to a Bank of America Merrill Lynch strategist. [...]
Wed, Mar 15, 2017 5:03:00 PM, Continue reading at the source
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and ... GlobeNewswire (press release) - Mar 13, 2017 HAYWARD, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (the “Company”) today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an ... Anthera Pharmaceuticals (ANTH) Stock: Dives On Secondary Public Offering - CNA Finance (press release) [...]
Mon, Mar 13, 2017 8:01:00 PM, Continue reading at the source
Anthera Pharmaceuticals Now Trading Below Cash Value. This Biotech Could Rise ... Seeking Alpha - Feb 22, 2017 Because of this, I love buying beaten-down biotech stocks that still have lots of upside potential as well as very strong, cash-rich balance sheets. Anthera Pharmaceuticals Inc (NASDAQ:ANTH): Ignore The Lawsuits - Insider Financial Top Stock Picking – Anthera Pharmaceuticals Inc (NASDAQ:ANTH), Tronox Ltd ... - Wall Street Times (press release) [...]
Wed, Feb 22, 2017 5:57:00 PM, Continue reading at the source
Anthera Pharmaceuticals downgraded at SunTrust, price target slashed to $1 from $6 MarketWatch - Dec 29, 2016 Anthera Pharmaceuticals Inc. shares ANTH, -5.64% were downgraded to hold from buy by SunTrust Robinson Humphrey on Thursday, after the company said one of its drugs had come up short in a study. [...]
Thu, Dec 29, 2016 12:59:00 PM, Continue reading at the source
Anthera Pharma plunges 66% after missing target in study MarketWatch - Dec 27, 2016 Anthera Pharmaceuticals Inc. ANTH, +1.21% lost roughly two-thirds of its market value in late trading Tuesday after the company announced that one of its drugs had come up short in a study. [...]
Tue, Dec 27, 2016 9:55:00 PM, Continue reading at the source
Anthera Pharmaceuticals Announces Continuation of SIMPLICITY Study of Sollpura ... GlobeNewswire (press release) - Dec 13, 2016 HAYWARD, Calif., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data Monitoring Committee (DMC) completed its pre-planned safety review of the SIMPLICITY clinical study of Sollpura ... [...]
Tue, Dec 13, 2016 1:30:00 PM, Continue reading at the source
Anthera Announces Leadership Transition in Preparation of Commercialization of ... GlobeNewswire (press release) - Dec 6, 2016 06, 2016 (GLOBE NEWSWIRE) -- Today the Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) Board of Directors announced J. Craig Thompson has been promoted to Chief Executive Officer. [...]
Tue, Dec 06, 2016 9:10:00 PM, Continue reading at the source